Abetimus is a selective immunosuppressive agent (a compound that selectively dampens down the immune system). Most patients with SLE have antibodies in their blood that are directed against double-stranded DNA (deoxyribonucleic acid). These antibodies are thought to be linked to the development of lupus kidney disease. Abetimus is a small piece of double-stranded DNA that has been designed to reduce circulating levels of these antibodies. When Abetimus is injected, the levels of these antibodies in the blood are lowered and this is expected to help reduce the patient’s likelihood of experiencing a ‘flare’.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
|L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Abetimus is an active ingredient of these brands:
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.